CMS expands coverage of Next Generation Sequencing for patients with inherited breast and ovarian cancer

Healthcare Finance: The Centers for Medicare and Medicaid Services is now covering Food and Drug Administration approved or cleared laboratory diagnostic tests using Next Generation Sequencing for patients with inherited ovarian or breast cancer.

As a result of the decision, more Medicare patients will have access to Next Generation Sequencing in managing other types of inherited cancers to reduce mortality and improve health outcomes.

Read article

Share